BGI Acquires 27 SOLiD(TM) 4 Systems for Whole Genome Resequencing

CARLSBAD, Calif. & SHENZHEN, China – Life Technologies Corporation (NASDAQ: LIFE) and BGI (formerly Beijing Genomics Institute) announced today that they have partnered to offer whole human genome resequencing on the SOLiD(TM) 4 System. BGI, one of the world’s largest genomic centers, has acquired 27 SOLiD 4 Systems, which will allow BGI to deliver 50 whole human genome sequences a month.

The SOLiD 4 System offers industry-leading throughput, speed, accuracy and flexibility for a wide variety of sequencing studies. The platform’s unprecedented accuracy is integral to whole human genome sequencing, such as the study of disease evolution as well as those driven by genetic mutations, such as cancer.

“The accuracy of the SOLiD 4 System helps ensure that scientists conducting genomic medicine studies can unearth those hard-to-find mutations that may drive specific diseases,” said Mark Gardner, Head of product management for the Genetic Systems Division of Life Technologies. “BGI’s capability will provide researchers across the globe access to the highest quality sequencing that our system generates.”

As a world-class research institution, BGI has established its own technical platforms based on large-scale genome sequencing, efficient bioinformatics analyses, and innovative genetic healthcare initiatives. With a focus in research and application in personalized healthcare, agriculture, conservation and bio-energy fields, BGI has made a great contribution to the development of genomics in the world through many distinguished achievements. BGI has research centers in the United States, Europe, Hong Kong, and mainland China. Whole human genome sequencing on the SOLiD 4 System will be available globally for scientific collaboration and sequencing services.

“BGI is changing how researchers accomplish their DNA sequencing, and by adding the SOLiD 4 System to our current sequencing offering, we will be able to deliver the fastest, most accurate and cost efficient whole genome sequencing service,” said Li, Jingxiang, Vice President of Genomics Operations for BGI. “We can secure sequence data for a complete whole human genome on 30x coverage that includes 100 gigabases of mapped data at an accuracy of 99.9%. Our partners can rely on the data and information to achieve their research goals.”

The SOLiD 4 System is for research use only, and not for use in diagnostic procedures.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: https://www.lifetechnologies.com.

About BGI

BGI (formerly known as Beijing Genomics Institute) was founded in Beijing on Sept 9th, 1999 with the mission of supporting the development of science and technology, building strong research teams, and promoting the development of scientific partnership in genomics field. With a goal toward excellence, high efficiency, and accuracy, BGI has successfully completed a large number of projects. These include sequencing one per cent of the human genome for the International Human Genome Project, contributing 10 percent to the International Human HapMap Project, carrying out research to combat SARS, being a key player in the Sino-British Chicken Genome Project, and completely sequencing the rice genome, the silkworm genome, and, most recently, the first Asian diploid genome. In 2007, BGI’s headquarters was relocated to Shenzhen and has become the largest genomic organization in the world. BGI, and its affiliates, BGI Americas and BGI Europe, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, supporting a variety of disease, agricultural, environmental, and related applications.

For more information, please visit www.genomics.cn.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.